Prothena Corporation plc (PRTA)
NASDAQ: PRTA · Real-Time Price · USD
10.28
+0.02 (0.19%)
Nov 5, 2025, 2:01 PM EST - Market open
Prothena Corporation Revenue
Prothena Corporation had revenue of $4.42M in the quarter ending June 30, 2025, a decrease of -96.65%. This brings the company's revenue in the last twelve months to $10.34M, down -95.24% year-over-year. In the year 2024, Prothena Corporation had annual revenue of $135.16M with 47.92% growth.
Revenue (ttm)
$10.34M
Revenue Growth
-95.24%
P/S Ratio
53.39
Revenue / Employee
$63,442
Employees
163
Market Cap
553.37M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 135.16M | 43.79M | 47.92% |
| Dec 31, 2023 | 91.37M | 37.47M | 69.50% |
| Dec 31, 2022 | 53.91M | -146.67M | -73.13% |
| Dec 31, 2021 | 200.58M | 199.72M | 23,414.30% |
| Dec 31, 2020 | 853.00K | 39.00K | 4.79% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
PRTA News
- 5 days ago - Prothena to Report Third Quarter 2025 Financial Results on November 6 - Business Wire
- 4 weeks ago - Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's Disease - Business Wire
- 2 months ago - Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference - Business Wire
- 2 months ago - Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program - Business Wire
- 3 months ago - Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy - Business Wire
- 3 months ago - Prothena Reports Second Quarter 2025 Financial Results and Business Highlights - Business Wire
- 3 months ago - Prothena to Report Second Quarter 2025 Financial Results on August 4 - Business Wire
- 4 months ago - Prothena Announces Corporate Restructuring - Business Wire